Assoc. Prof. Ozan Balakan

Assoc. Prof. Ozan Balakan
Academic Title :
Assoc. Prof.

Assoc. Prof. MD. Ozan Balakan is a Medical Oncology specialist at Liv Hospital Bahcesehir. He possesses over 20 years of clinical experience in medicine and more than 12 years of dedicated practice in medical oncology, providing advanced care and treatment protocols for cancer patients.

Education and Academic Qualifications

  • Graduated from Istanbul University, Faculty of Medicine.
  • Completed residency training in Internal Medicine at Dicle University Faculty of Medicine in 2005.
  • Completed sub-specialty fellowship training in Medical Oncology at Gaziantep University Faculty of Medicine in 2012.

Areas of Interest

  • Breast Cancer in Turkey
  • Gastrointestinal System Cancers
  • Lung Cancer
  • Neuroendocrine Tumors
  • Central Nervous System Tumors
  • Targeted Therapy for Tumors
  • Research Assistant in Internal Medicine at Dicle University Faculty of Medicine (2001 - 2005).
  • Specialist Physician at Private Ibni Sina Hospital in Osmaniye (2005 - 2006).
  • Specialist Physician at Private Vatan Medical Center in Kahramanmaras (2006 - 2007).
  • Assistant Professor in Internal Medicine at Selcuk University Faculty of Medicine (2007 - 2008).
  • Military Physician in Endocrinology at Gulhane Military Medical Academy in Ankara (2008 - 2009).
  • Assistant Professor and Fellow in Medical Oncology at Gaziantep University Faculty of Medicine (2009 - 2012).
  • Assistant Professor, later Associate Professor and Head of the Medical Oncology Department at Kahramanmaras Sutcu Imam University (2012 - 2016).
  • Medical Oncology Specialist at Reyap Istanbul Hospital.
  • Associate Professor of Medical Oncology at Liv Hospital Bahcesehir.
  • Turkish Society of Medical Oncology
  • Anatolian Society of Medical Oncology
  • The Relationship between Urotensin II and its Receptor and the Clinicopathological Parameters of Breast Cancer, Medical Science Monitor (2014).
  • Expression of PARP1 Gene in Breast Cancer Patients, International Journal of Hematology and Oncology (2013).
  • Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third or fourth line treatment: A retrospective multicenter experience, Spandidos Publications (2013).
  • Helicobacter pylori in primary gastric lymphoma and gastric cancer: A clinicopathologic and prognostic assessment, Journal of Microbiology and Infectious Diseases (2013).
Share :